Myocardial capillary density after neuropeptide Y antagonist administration in normal and high-fat diet C57BL6 mice


1 Department of Physiology, Sanandaj University of Medical Sciences, Sanandaj, Iran

2 Applied Physiology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

3 Department of Anatomy, Isfahan University of Medical Sciences, Isfahan, Iran

4 Neurogenic Inflammatory Research Center and Department of Physiology, Mashhad University of Medical Sciences, Mashhad, Iran


Background: Neuropeptide Y (NPY), a 36 amino acid peptide, has several effects on cardiovascular system. It is demonstrated that the angiogenic activity of NPY is similar to fibroblast growth factor and vascular endothelial growth factor (VEGF). The aim of this study was to evaluate the effect of systemic administration of antagonist of NPY receptor (BIIE0742) on coronary angiogenesis in normal and diet-induced obese animals.
Materials and Methods: Twenty-four male mice were received high-fat diet (HFD) or normal diet (ND) for 14 weeks. Then, each group was randomized to the treatment of antagonist of NPY receptor (BIIE0246) or saline as following: ND+ BIIE0246 (100 μl/kg; i.p.), ND+ saline, HFD+ BIIE0246, HFD+ saline. After 14 days, blood samples were taken, and myocardial tissue (left ventricle) from all experimental groups was evaluated by immunohistochemistry.
Results: Serum VEGF concentration and VEGF: Soluble VEGF receptor (sVEGFR)-1 ratio in obese animals was higher than normal group. Administration of BIIE0246 significantly reduced serum VEGF and VEGF: sVEGFR-1 ratio and increased serum sVEGFR-1 concentrations in obese animals (P < 0.05). In normal animals, BIIE0246 increased serum sVEGFR-1 level and decreased VEGF: sVEGFR-1 ratio. Serum nitrite did not alter after administration of BIIE0246 in both groups (P > 0.05). Myocardial capillary density expressed as the number of CD31 positive cells/mm2 was reduced after NPY antagonist treatment in obese and normal animals (P > 0.05).
Conclusion: Administration of NPY antagonist impairs myocardial capillary density, reduces angiogenic factors and elevates anti-angiogenic factors, and there are no differences between obese and normal animals.


Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-4.  Back to cited text no. 1
Carmeliet P, Collen D. Molecular analysis of blood vessel formation and disease. Am J Physiol 1997;273:H2091-104.  Back to cited text no. 2
Lassaletta AD, Chu LM, Sellke FW. Therapeutic neovascularization for coronary disease: Current state and future prospects. Basic Res Cardiol 2011;106:897-909.  Back to cited text no. 3
Mukouyama YS, Shin D, Britsch S, Taniguchi M, Anderson DJ. Sensory nerves determine the pattern of arterial differentiation and blood vessel branching in the skin. Cell 2002;109:693-705.  Back to cited text no. 4
Bas HD, Baser K, Yilmaz S, Tuncel AF, Yaman B, Abaci A. The relationship of plasma neuropeptide Y levels with coronary collateral development. Coron Artery Dis 2014;25:73-8.  Back to cited text no. 5
Matyal R, Chu L, Mahmood F, Robich MP, Wang A, Hess PE, et al. Neuropeptide Y improves myocardial perfusion and function in a swine model of hypercholesterolemia and chronic myocardial ischemia. J Mol Cell Cardiol 2012;53:891-8.  Back to cited text no. 6
Robich MP, Matyal R, Chu LM, Feng J, Xu SH, Laham RJ, et al. Effects of neuropeptide Y on collateral development in a swine model of chronic myocardial ischemia. J Mol Cell Cardiol 2010;49:1022-30.  Back to cited text no. 7
Lee EW, Grant DS, Movafagh S, Zukowska Z. Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice. Peptides 2003;24:99-106.  Back to cited text no. 8
Lee EW, Michalkiewicz M, Kitlinska J, Kalezic I, Switalska H, Yoo P, et al. Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest 2003;111:1853-62.  Back to cited text no. 9
Movafagh S, Hobson JP, Spiegel S, Kleinman HK, Zukowska Z. Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors. FASEB J 2006;20:1924-6.  Back to cited text no. 10
Zhang L, Bijker MS, Herzog H. The neuropeptide Y system: Pathophysiological and therapeutic implications in obesity and cancer. Pharmacol Ther 2011;131:91-113.  Back to cited text no. 11
Zukowska Z, Grant DS, Lee EW. Neuropeptide Y: A novel mechanism for ischemic angiogenesis. Trends Cardiovasc Med 2003;13:86-92.  Back to cited text no. 12
Pandey V, Vijayakumar MV, Ajay AK, Malvi P, Bhat MK. Diet-induced obesity increases melanoma progression: Involvement of Cav-1 and FASN. Int J Cancer 2012;130:497-508.  Back to cited text no. 13
Alasvand M, Rashidi B, Haghjooy Javanmard S, Khazaei M. Effect of blockade of neuropeptide Y receptor on aortic intima-media thickness and adipose tissue characteristics in normal and obese mice. Iran J Basic Med Sci 2015;18:443-8.  Back to cited text no. 14
Alasvand M, Rashidi B, Javanmard SH, Akhavan MM, Khazaei M. Effect of blocking of neuropeptide Y Y2 receptor on tumor angiogenesis and progression in normal and diet-induced obese C57BL/6 mice. Glob J Health Sci 2015;7:46883.  Back to cited text no. 15
Tahergorabi Z, Khazaei M. A review on angiogenesis and its assays. Iran J Basic Med Sci 2012;15:1110-26.  Back to cited text no. 16
Sainsbury A, Schwarzer C, Couzens M, Fetissov S, Furtinger S, Jenkins A, et al. Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice. Proc Natl Acad Sci U S A 2002;99:8938-43.  Back to cited text no. 17
Zhang L, Riepler SJ, Turner N, Enriquez RF, Lee IC, Baldock PA, et al. Y2 and Y4 receptor signaling synergistically act on energy expenditure and physical activity. Am J Physiol Regul Integr Comp Physiol 2010;299:R1618-28.  Back to cited text no. 18
Allison SJ, Baldock P, Sainsbury A, Enriquez R, Lee NJ, Lin EJ, et al. Conditional deletion of hypothalamic Y2 receptors reverts gonadectomy-induced bone loss in adult mice. J Biol Chem 2006;281:23436-44.  Back to cited text no. 19
Wu FT, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS. A systems biology perspective on sVEGFR1: Its biological function, pathogenic role and therapeutic use. J Cell Mol Med 2010;14:528-52.  Back to cited text no. 20
Chang YT, Chang MC, Wei SC, Tien YW, Hsu C, Liang PC, et al. Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas 2008;37:145-50.  Back to cited text no. 21
Khazaei M, Fallahzadeh AR, Sharifi MR, Afsharmoghaddam N, Javanmard SH, Salehi E. Effects of diabetes on myocardial capillary density and serum angiogenesis biomarkers in male rats. Clinics (Sao Paulo) 2011;66:1419-24.  Back to cited text no. 22